Ramipril 5 Mg Capsules Suppliers & Bulk Manufacturers
Available Forms: Capsules/Tablets
Available Strengths: 1.25 mg, 2.5 mg, 5 mg, 10 mg, and 20 mg
Reference Brands: Altace(US), Ramace (India)
Category:
Heart Disorder
Ramipril is an ACE inhibitor that blocks the formation of angiotensin II, leading to vasodilation, reduced blood pressure, and decreased workload on the heart. It effectively prevents strokes, heart attacks, and heart failure progression, improving cardiovascular health, reducing symptoms, and supporting long-term management of hypertension and heart disease.
Ramipril 5 mg Capsules is available in Capsules/Tablets
and strengths such as 1.25 mg, 2.5 mg, 5 mg, 10 mg, and 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ramipril 5 mg Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ramipril 5 mg Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ramipril capsules and tablets, marketed as Altace in the US and as generic Ramipril across the EU, are approved for hypertension, heart failure, and cardiovascular risk reduction. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and worldwide availability of ramipril, enabling effective blood pressure and cardiovascular management globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing